Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.45 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172351 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL8634662 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL14302595 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL2295882 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL1512965 | 1.00 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL22749240 | 0.98 | SLC7A5 (0.60) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL1025464 | 0.98 | SLC7A5 (0.60) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL21578367 | 0.96 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL26471760 | 0.96 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL27984597 | 0.84 | SLC1A1 (0.46) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110016020-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109384778-A | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 铁木医药有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109369635-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-108912111-A | compounds and pharmaceutical compositions | 铁木医药有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105408328-B | sGC stimulators | 铁木医药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100029575-A1 | N-Oxides of Kappa Receptor Peptides | CARA THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| CN-101454338-A | N-oxides of kappa opioid receptor peptides | CARA THERAPEUTICS INC (US) | 2009-06-10 | — | — | CN | disclosed |
| CN-101454017-A | Method for elevating prolactin in mammals | CARA THERAPEUTICS INC (US) | 2009-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029575-A1 | N-Oxides of Kappa Receptor Peptides | OPRD1, OPRK1, OPRM1 | SLC7A5 975/4885SLC1A2 1101/4885SLC1A1 270/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | SLC7A5 75/4885SLC1A2 236/4885SLC1A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.